Angiodynamics INC Form 4 insider transactions

Stephen Trowbridge, EVP and CFO of AngioDynamics, reports the disposal of common stock to cover tax withholding obligations related to vesting restricted stock units.

James Clemmer, President and CEO of AngioDynamics, reports acquisition of common stock, performance rights, and stock options.

Laura Piccinini, SVP International at AngioDynamics, disposed of 1,983 shares of common stock to satisfy tax withholding obligations related to vesting restricted stock units.

Warren Nighan Jr., SVP of Quality and Regulatory at AngioDynamics, disposed of 735 shares to cover tax obligations related to vesting restricted stock units.

CEO James Clemmer disposed of 8,307 shares of AngioDynamics common stock to satisfy tax withholding obligations related to vesting restricted stock units.

Chad Thomas Campbell, SVP/GM of Vascular Access at AngioDynamics, Inc., disposed of 1,025 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Warren Nighan, SVP of Quality and Regulatory at AngioDynamics, reports the acquisition of restricted stock units, performance rights, and stock options in a Form 4 filing.

Laura Piccinini, SVP International at AngioDynamics, reports the acquisition of common stock, performance rights, and stock options.

Chad Thomas Campbell, SVP/GM, Vascular Access at AngioDynamics, reports the acquisition of common stock, performance rights, and non-qualified stock options.

Director Reed Jan Stern acquired 20,541 shares of AngioDynamics common stock as part of his annual compensation, which immediately vested.

Director Wesley Johnson acquired 20,541 shares of AngioDynamics common stock as part of his annual compensation for serving as a director.

Director Michael Tarnoff acquired 20,541 shares of AngioDynamics common stock as part of his annual compensation.

James Clemmer, President and CEO of AngioDynamics, reports the acquisition of restricted stock units and performance rights, along with stock options.

Director Howard W. Donnelly acquired 20,541 shares of AngioDynamics common stock as part of his annual compensation.

Director Lorinda Burgess receives restricted stock units and disposes of shares of AngioDynamics, Inc.

Stephen Trowbridge, EVP and CFO of AngioDynamics, reports the acquisition of common stock, performance rights, and stock options.

Director Karen A. Licitra reports acquiring 20,541 shares of AngioDynamics common stock as part of annual compensation.

Director Eileen O'Shea Auen acquired 20,541 shares of AngioDynamics common stock as part of her annual compensation for serving on the board.

AngioDynamics' CEO, James C. Clemmer, recently purchased 10,000 shares of the company's common stock at an average price of $6.70 per share.

Stephen Trowbridge, EVP and CFO of AngioDynamics, reports acquiring 1,927 shares of common stock through the company's Employee Stock Purchase Plan.